Allergan confirms (but won't name) 2nd suitor
This article was originally published in Scrip
Executive Summary
Allergan is vehemently opposed to an acquisition by Valeant Pharmaceuticals, but the maker of Botox (onabotulinumtoxinA) and Restasis (cyclosporine) disclosed on 3 November that it has been approached by an unnamed second suitor.